linjc16/ctgov huggingface dataset:
Sonographic Venous Doppler Imaging in End-Stage Renal Disease

Study Overview
=================
Brief Summary
-----------------
Patients with end-stage renal disease (ESRD) may visit to emergency services for urgent hemodialysis or other reasons. Hemodialysis application in emergency conditions is generally not as optimal as in dialysis units. It takes time to provide suitable conditions (personnel and equipment), the length of stay of patients in the emergency services is prolonged, and this may cause disruption of patient care in these areas where rapid patient care is provided. Therefore, the management of ESRD patients continues to be one of the serious problems faced by emergency physicians. Sonographic evaluation of the venous system (vena cava inferior, hepatic, portal and renal vein) may be an alternative diagnostic method for need for urgent hemodialysis. Hereby, patients who don't need hemodialysis safely can be discharged from emergency services. Studies conducted so far have generally been based on predicting cardiorenal AKI and renal poor outcomes and have been designed in general ICU conditions. In this study, the researchers aimed to determine the diagnostic value of sonographic venous Doppler imaging the need for urgent hemodialysis in ESRD patients in the emergency services.

Official Title
-----------------
The Value of Venous Doppler Imaging in Predicting the Indication of Emergency Dialysis in Patients With End-Stage Renal Disease

Conditions
-----------------
Emergent Dialysis, Venous Doppler Ultrasound

Intervention / Treatment
-----------------
* Diagnostic Test: Sonography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with end-stage renal disease Exclusion Criteria: Who are pregnant, With cirrhosis and liver malignancy, Who do not give consent for the study, Arrest presentation Unable to scan in the first six hours

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 110 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Sonography|Sonographic Venous Doppler Imaging|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The diagnostic accuracy of sonographic venous Doppler imaging for the need for urgent hemodialysis |  | 1 year |
Evaluation of Ivermectin Mucoadhesive Nanosuspension as Nasal Spray in Management of Early Covid-19

Study Overview
=================
Brief Summary
-----------------
Ivermectin showed a strong viricidal effect upon covid19 virus in vitro as proved by many authors according to many studies , covid virus stay in postnasal space for 4 days before starting general manifestation, so ivermectin mucoadhesive nanosuspension sprayed inside the nose and post nasal space may help in early management of covid19 and may play a great rule in prophylaxis as well

Detailed Description
-----------------
150 patient with early covid is devided into two groups first group will receive regular protocol of drugs second group will receive ivermectin nasal spray in addition to regular protocl of drugs

Official Title
-----------------
Faculty of Medicine ,South Valley University

Conditions
-----------------
Covid19

Intervention / Treatment
-----------------
* Drug: intranasal ivermectin spray


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: early covid19 pateints Exclusion Criteria: children and pregnant women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: intranasal Ivermectin group<br>Ivermectin group Patients who will receive intranasal ivermectin | Drug: intranasal ivermectin spray<br>* usage of ivermectin as intranasal spray for treating early covid patiens<br>|
| Other: Control group<br>patients who will receive regular protocol drugs | Drug: intranasal ivermectin spray<br>* usage of ivermectin as intranasal spray for treating early covid patiens<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| progression of covid 19 clinical picture | progress of Symptoms ( Fever ,Cough, Sore Throat, Myalgia,Diarrhea, Shortness of Breath)with radiological assesment and blood tests | [ Time Frame: within 14 days after enrollement ] | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ivermectin intranasal spray in covid19
Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma

Study Overview
=================
Brief Summary
-----------------
The investigators analyzed clinical outcome in DLBCL patients according to age group to define the impact of EBV status on the clinical outcome.

Detailed Description
-----------------
Epstein-Barr virus (EBV) positive diffuse large B-cell lymphoma (DLBCL) has been recognized as a new provisional entity in the 2008 World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissue. This lymphoma is defined as EBV+ clonal B-cell proliferation in immunocompetent adults older than 50 years. To denote patient age in definition of this disease, age cutoff was defined as older than 50 years. However, this cutoff is clearly arbitrary without any scientific background. the knowledge on EBV+DLBCL in young adult is very scanty. This EBV+DLBCL in young adult can be the same disease entity or it can be a distinct disease form EBV+DLBCL of elderly.

Official Title
-----------------
The Impact of the Epstein-Barr Virus Status on Clinical Outcome in Diffuse Large B Cell Lymphoma

Conditions
-----------------
Diffuse Large B-cell Lymphoma

Intervention / Treatment
-----------------
* Other: EBER


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pathologically confirmed de novo DLBCL, according to the World Health Organization (WHO) classification: registered in Samsung Medical Center (SMC) Lymphoma Cohort Study I/II (ClinicalTrials.gov Identifier: NCT00822731, NCT01877109) or identified from Asan Medical Center (AMC) medical database: adequate amount and quality of paraffin-embedded biopsy specimen or unstained slides for EBV-encoded RNA (EBER) in situ hybridization. Exclusion Criteria: Patients with unknown EBV status, primary central nervous system (CNS) lymphoma, post-transplant lymphoproliferative disorders (PTLDs), and HIV-positive DLBCL were excluded in the study.

Ages Eligible for Study
-----------------
Minimum Age: 17 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| EBER+ AMC<br>EBV+DLBCL patients in Asan Medical Center | Other: EBER<br>* EBV RNA was detected by an in situ hybridization (ISH) technique using the EBV ISH kit (Leica Microsystems, Bannockburn, IL, USA).<br>|
| EBER+ SMC<br>EBV+DLBCL patients in Samsung Medical Center | Other: EBER<br>* EBV RNA was detected by an in situ hybridization (ISH) technique using the EBV ISH kit (Leica Microsystems, Bannockburn, IL, USA).<br>|
| EBER- SMC<br>EBV-DLBCL patients in Samsung Medical Center | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| overall survival |  | Two years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
diffuse large B-cell lymphoma, Ebstein-Barr Virus
Tooth Loss in Periodontitis Patients

Study Overview
=================
Brief Summary
-----------------
Tooth loss in periodontitis patients is associated with patient and site factors as well as with treatment provided. Not much is known about long-term tooth loss in periodontitis patients in private practice in the UK. The study plans to follow-up 200 subjects with periodontitis (and currently on maintenance therapy) for 5 years. The effect of treatment provided, site and patient risk factors on tooth loss will be studied.

Official Title
-----------------
Tooth Loss in Periodontitis Patients on Long-term Maintenance in Private Practice

Conditions
-----------------
Periodontitis

Participation Criteria
=================
Eligibility Criteria
-----------------
INCLUSION CRITERIA: Initial diagnosis of chronic or aggressive periodontitis (Lindhe et al. 1999, Lang et al. 1999), with at least two sites with PPD and CAL ≥5mm Diagnosed and treated by the same periodontist (LN) Willing to give written informed consent for study participation Willing to undergo SPT as per standard of care for at least 5 years EXCLUSION CRITERIA: Serious medical history that prevents patients from undergoing dental treatment History of rheumatic fever, heart murmur, mitral valve prolapse, artificial heart valve or other conditions requiring prophylactic antibiotic coverage prior to invasive dental procedures Current alcohol or drug abuse Self-reported pregnancy or lactation Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may compromise trial participation and/or interpretation of trial results and, in the judgement of the investigator, would make the subject inappropriate for entry into this trial

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tooth loss |  | 5 years |
Magnesium Effect on Embryonal PR Interval

Study Overview
=================
Brief Summary
-----------------
Magnesium is a known treatment for neuroprotection in preterm labor before 32 week of gestation. High concentration of Magnesium in the blood stream known as cause of conduction abnormalities and ECG changes such us prolonged QT, QRS and PR in about. The goal of our work is to evaluate the PR intervals in embryos after maternal treatment with magnesium during preterm labor.

Detailed Description
-----------------
We will recruit 25 woman with threaten preterm labor, magnesium blood level and PR interval will be evaluated before magnesium loading dose (4gr) and 20 minutes after the loading dose. PR interval will be evaluated by Mitral-Aorta Doppler.

Official Title
-----------------
Magnesium Effect on Embryonal PR Interval

Conditions
-----------------
Preterm Labor

Intervention / Treatment
-----------------
* Diagnostic Test: Trans abdominal sonography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women at risk for preterm labor before 32 week of gestation Exclusion Criteria: Fetal malformations Maternal Lupus Fetal conduction abnormalities

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Women in risk for preterm labor<br>Women in risk for preterm labor treated with magnesium. | Diagnostic Test: Trans abdominal sonography<br>* Trans abdominal sonography in order to measure fetal PR interval.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prolonged PR interval | PR will be measured by Mitral-aorta doppler | 20 min after magnesium treatment |
USZ BioResource COVID-19

Study Overview
=================
Brief Summary
-----------------
Mono-centric. Blood sampling for biobank development, including linkage to patient data (resource for research on COVID19).

Official Title
-----------------
Development of a SARS-CoV-2 Research Biobank and Databank

Conditions
-----------------
COVID19

Intervention / Treatment
-----------------
* Other: blood sampling for biobank


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: m/f age > 18 years SARS-CoV-2 infektion (according to WHO guideline) hospitalisation, general ward acceptable language knowledge voluntary IFC and biobank appendix Exclusion Criteria: contra indication for blood sampling

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: blood sampling for biobank|blood sampling for biobank|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| blood sampling for biobank | development of a biobank | 2 years |
Study to Evaluate the Abuse Potential of AZD7325 in Healthy Recreational Central Nervous System (CNS) Depressant Users

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to examine the abuse potential of AZD7325.

Official Title
-----------------
A Single-Centre, Single-Dose, Double-Blind, Randomized, Placebo- and Active-Controlled Crossover Study to Evaluate the AbusePotential of AZD7325 in Healthy Recreational CNS Depressant Users

Conditions
-----------------
Recreational CNS Depressant Use

Intervention / Treatment
-----------------
* Drug: Lorazepam
* Drug: AZD7325
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Recreational CNS depressant use, defined as at least 10 lifetime occasions of non-medical use of drugs with depressant/sedative properties and at least 1 non-medical use in the year prior to screening Body mass index (BMI) within the range of 19.0 to 33.0 kg/m2, inclusive, and a minimum weight of 50.0 kg at screening Willing and able to abide by all study requirements and restrictions Exclusion Criteria: Unwillingness of inability to abstain from recreational drug use for the duration of the study from screening until follow-up Positive breath alcohol test prior to dosing Clinically significant abnormalities on physical examination, medical history, 12-lead ECG, vital signs, or safety laboratories

Ages Eligible for Study
-----------------
Minimum Age: 18 Months
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: A<br>Placebo | Drug: Placebo<br> <br> |
| Active Comparator: B<br>Lorazepam | Drug: Lorazepam<br>* mg, oral dose<br>|
| Active Comparator: C<br>Lorazepam | Drug: Lorazepam<br>* mg, oral dose<br>|
| Active Comparator: D<br>Lorazepam | Drug: Lorazepam<br>* mg, oral dose<br>|
| Experimental: E<br>AZD7325 | Drug: AZD7325<br>* mg, oral dose<br>|
| Experimental: F<br>AZD7325 | Drug: AZD7325<br>* mg, oral dose<br>|
| Experimental: G<br>AZD7325 | Drug: AZD7325<br>* mg, oral dose<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Analog Scales |  | Daily during Visit 2 through 9 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Columbia Suicide-Severity Rating Scale |  | Prior to each treatment period | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Recreational CNS depressant, Abuse liability, Abuse potential, Healthy Recreational CNS Depressant Users
Incidence of Retinopathy and Associated Risk Factors in Children and Young Adults With Type 1 Diabetes in Denmark

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to clarify the current diabetic status, including development of complications, in a nationwide cohort of type 1 diabetics, who were last examined together in a large study in 1995. These youngsters were originally participating in a nationwide study of children with type 1 diabetes in Denmark back in 1986. The investigators will try to establish risk factors for developing diabetic retinopathy. The investigators will have emphasis on retinal vessel geometry and the possibilities for early detection of reversible retinal changes, and prediction of other vascular complications.

Official Title
-----------------
Incidence of Retinopathy and Associated Risk Factors in Children and Young Adults With Type 1 Diabetes in Denmark

Conditions
-----------------
Type 1 Diabetes, Diabetic Retinopathy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participation in the follow-up study in 1995 Exclusion Criteria: No retinal photographs from 1995

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Young Danish adults with type 1 diabetes<br>This is an observational study with no interventions. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of diabetic retinopathy and proliferative diabetic retinopathy | Using the ETDRS grading protocol the degree of retinopathy in 2011 will be assessed by grading 7-field fundus photographs taken at follow-up examination. This will be related to the degree of retinopathy found in the patients in 1995, where the last study of the cohort took place. | 16 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vessel diameters as a predictor of diabetic retinopathy and proliferative diabetic retinopathy | Using the computer software named IVAN we will assess the average vessel diameters around the optic disc on fundus photos from 1995. This we will relate to the degree of retinopathy in 2011 to see if vessel diameters predicts diabetic eye complications. | 16 years |
Promoting Radon Testing Via Smartphone App: A Clinical Trial in a High Radon State

Study Overview
=================
Brief Summary
-----------------
This research will compare (1) the effectiveness of a mobile radon-education app (vs. traditional brochures) and (2) that of the radon app with in-app reminders (vs. the radon app without in-app reminders and the no app use with postal reminders) to increase radon awareness and testing among North Dakotans. The prevalence of exceptionally high levels of residential radon in ND, coupled with public's poor understanding of this hazard, is a critical public health problem.

Official Title
-----------------
Promoting Radon Testing Via Smartphone App: A Clinical Trial in a High Radon State

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Other: The radon app
* Other: Print brochure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The principal eligibility criterion is that participants own a smartphone. Exclusion Criteria: The principal exclusion criterion is previous testing for radon within the past two years.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Print brochures<br>Participants assigned to the print brochure group will receive three educational print brochures about radon published by EPA via postal mails for three months (one per each month). | Other: Print brochure<br>* Participants will receive print brochures.<br>|
| Experimental: The radon app<br>Participants assigned to the radon app group will be asked to use the radon app for three months where they will be exposed to mobile friendly educational content that is repurposed from educational print brochures about radon published by EPA. | Other: The radon app<br>* Participants will be asked to use the radon app.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ordering a free radon test kit | The rate at which participants order a free radon test kit | Through the study completion - 3 months | 
| Using the radon test kit | The rate at which participants use the radon test kit to test their houses | Through the study completion - 3 months | 
| Change from baseline radon knowledge at 3 months | Participants' knowledge about radon and its dangers, how to protect themselves from radon, etc. | Change from baseline knowledge level to the completion of study at 3 months |